Glenmark Pharmaceuticals Ltd

As per the Code of Conduct of Prevention of Insider Trading and pursuant to the provisions of the SEBI (PIT) Regulations 2015 the Company has intimated its Directors and Designated Persons regarding closure of trading window from December 31 2025 to February 1 2026 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31 2025.